REDUCER I
OBSERVATIONAL STUDY

LONG TERM SAFETY AND EFFECTIVENESS RESULTS AND FEWER EMERGENCY DEPARTMENT VISITS CONTINUE TO SUPPORT THE TREATMENT OF REAL-WORLD PATIENTS SUFFERING FROM REFRACTORY ANGINA WITH THE SHOCKWAVE REDUCER[1]

REDUCER I is a prospective, open-label, multi-center, international, post-market study which collects long-term data of patients with refractory angina treated with the Reducer.

RESULTS

REDUCER I 12-month results show that patients receiving a Reducer device achieved a clinically significant increase in quality of life and functional capacity.

Seattle Angina Questionnaire
(Increasing Score is Better)



Primary Endpoint – CCS Class at 12 Months

- 70.5% with ≥1 Class Improvement*
- 25.5% ≥2 Classes Improvement*

*Paired analysis for those with both baseline AND 12mo CCS class assessment



SUSTAINED OVER TIME

REDUCER I 12-month results demonstrate sustained improvement in angina severity and in quality of life up to three years.

CCS and SAQ Improvements Sustained Through Three Years



	Baseline	6mo	1yr	2yr	3yr
No. With CCS Class	363	346	327	257	217
No. With SAQ Score	352	323	305	235	199

One-year outcomes show continued safety and effectiveness

Emergency Department (ED) visits within 12 months significantly decreased in terms of visits per patients and the total number of ED visits decreased by 65.6%.

BEFORE Reducer Implant

- 33.1% (97/293) with ED visit
- 192 total ED visits
- 0.66 ± 2.13 visits per pt

AFTER Reducer Implant

- 13.3% (39/293) with ED visit
- 66 total ED visits
- 0.23 ± 1.01 visits per pt (p<0.0001)*

*Based on Wilcoxon Signed Rank test.



Reducer I 12-month results show that Reducer implantation is safe; supported by a low MACE rate (2.0% Cardiac Death, 0.6% Stroke, 5.6% Myocradial Infarction) at 12 months.

KEY TAKEAWAYS FROM THE REDUCER I 12-MONTH RESULTS:

- REDUCER-I evaluated the Shockwave Coronary Sinus Reducer in real-world patients with refractory angina despite optimal medical therapy and limited revascularization options
- One-year outcomes show continued safety and effectiveness:
  - Low MACE rate
  - Positive CCS and QoL improvements
  - Reduction in emergency department visits
- Improvements in CCS and QoL were sustained through 3 years

FOOTNOTES

1. Verheye, S. Results from the REDUCER-I Study. ESC 2024.

CAUTION In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use.
The Reducer is subject of Investigational testing and is being studied in the COSIRA II trial in Canada.
The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.neovasc.com

SHOCKWAVE REDUCER

Johnson&Johnson MedTech

SHOCKWAVE MEDICAL